MitoGel™ is potentially the first non-surgical, renal-sparing, local treatment for low-grade UTUC. MitoGel is a sustained release formulation of Mitomycin C in the upper urinary tract. UroGen has obtained Orphan Drug Designation for MitoGel for UTUC.

Read More >

VesiGel™ is potentially the first non-surgical, local chemoablation therapy for the treatment Low Grade NMIBC. VesiGel is a sustained release formulation of high dose Mitomycin C for the effective delivery and prolonged tissue exposure.

Read More >

Vesimune™ is a TLR-7 agonist-based formulation for local intravesical delivery.  Vesimune is being developed as a potential treatment for CIS. UroGen has obtained Orphan Drug Designation for Vesimune for the treatment of CIS.

 

Read More >

About UroGen Pharma

UroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC.  In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.

Read More >